Achilles Therapeutics Raises £52.7 Million in an Oversubscribed Series C Financing to Further Advance the Development of Personalised T cell Therapies to Treat Solid Tumours
Achilles Therapeutics (“Achilles”), a clinical-stage biopharmaceutical company developing personalised T cell therapies targeting clonal neoantigens, a novel class of tumour target, today announced it has raised £52.7 million in an oversubscribed Series C financing. OrbiMed, Boxer Capital of Tavistock Group, and other prominent US-based, healthcare-focused institutional investors join existing investors including RA Capital, Syncona, Forbion, Invus, Perceptive Advisors and Redmile Group.
